Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 7/20 | 0.49 |
| ▸ | CA2 | P00918 | 7/20 | 0.49 |
| ▸ | CA9 | Q16790 | 7/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055080 | 0.86 | CA12 (0.45) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL20381100 | 0.86 | TDP1 (0.54) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL3303105 | 0.85 | TDP1 (0.42) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL3312327 | 0.83 | CA12 (0.45) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL30206955 | 0.82 | TDP1 (0.55) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6518816 | 0.81 | TDP1 (0.45) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL5190585 | 0.79 | CA12 (0.70) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL3308055 | 0.79 | CA1 (0.48) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL3308060 | 0.79 | CA1 (0.48) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6937740 | 0.79 | CA12 (0.62) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2061751-A1 | NITRATE ESTERS OF AMINOALCOHOLS | Novartis Ag (CH) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008031811-A1 | NITRATE ESTERS OF AMINOALCOHOLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | NOS2, NOS1, NOS3 | CA12 3887/4885CA1 4310/4885CA2 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.